iCOR Medical, LLC appears in FDA records as the applicant for iCOR Beat, a Class II cardiovascular device. The submission K260383 was received on February 5, 2026, and decided on November 2, 2026, with a substantially equivalent decision under the traditional review track. The filing lists product code MWJ, regulation 21 CFR 870.2800, and the device name Electrocardiograph, Ambulatory (Without Analysis). Company pages describe the product as a disposable ambulatory cardiac monitor and state a mission centered on simplifying ambulatory cardiac monitoring. [1][2][9]

The K260383 filing and its scope

K260383 identifies iCOR Medical, LLC as applicant and iCOR Beat as the device, with a decision date of November 2, 2026, and decision code SESE, described as Substantially Equivalent. The record carries product code MWJ, advisory committee CV, and regulation number 870.2800. The submission is marked Traditional, not a third-party review, and the statement field indicates a Summary. The device classification shown is Class 2. [1][9]

The supplied collection holds one linked 510(k) record, and its decision count is one SESE. The record sample contains the same single entry, so the sample and collection denominators coincide here; neither figure describes total company sales, total portfolio, or safety performance. [1]

Device description as published by the company

iCOR Medical's own site calls Beat a one-ounce, disposable ambulatory cardiac monitor intended to support earlier, clearer diagnoses. A technical specifications page lists a weight of 1 ounce (28 grams), a slim profile, monitoring duration of up to 30 (as truncated in the supplied excerpt), water resistance described as shower safe, smartphone data transmission, and a lowest cost per test claim. These are company statements, not FDA findings. [3][4]

The site also references a BeatSuite mobile app and Beat instructions for use, and lists contact details at 4350 NW 120th Avenue, Coral Springs, FL, with an email address and phone number. The FDA filing carries the same Coral Springs, FL address and names Steve Lica as contact; a filing address is not treated here as a verified headquarters. [1][2][4]

Radio and regulatory footprint

An FCC entry for identifier 2BR7H-BEAT01, attributed to Icor Medical Inc., describes a unit sent for approval that contains only BLE, with equipment class Digital Transmission System and a latest application date of November 16, 2026. The grantee name differs from the FDA applicant name, and no parent, subsidiary, or brand relationship between the two names is verified in the public documents. [7]

A separate FDA premarket notification listing includes a row for iCOR Beat with a Summary statement and CV advisory committee, consistent with the K260383 record. The listing also shows unrelated applicants and devices, which are not part of this company's portfolio. [6]

Published commentary and identity limits

A company news post dated October 30, 2026, discusses sleep and heart health in relation to Beat and cites a figure about patients with atrial fibrillation also having obstructive sleep apnea. That figure is the publisher's statement and is not reproduced here as clinical guidance. [8]

Beyond the K260383 clearance, the FCC entry, and company pages, the public documents do not establish ownership, customers, commercial availability, pricing in practice, or independent testing results. Those points remain unknown. [1][4][7]